Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed...
-
Detroit, MI, April 30, 2026 (GLOBE NEWSWIRE) -- The College for Creative Studies (CCS) has named Allison J. Puff as Provost and Vice President for Academic Affairs, the institution’s chief academic...
-
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for...
-
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to...
-
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DMEKey data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing...
-
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal...
-
WASHINGTON, April 28, 2026 (GLOBE NEWSWIRE) -- Compass Lexecon, a subsidiary of FTI Consulting, Inc. (NYSE: FCN), today announced that Dr. Ori Heffetz, a Professor of Economics at the S.C....
-
Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als aufgehoben...
-
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitisOnce-daily ZORYVE cream was well...
-
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido recommended in 2026...